购物车0
产品总数：61470
| 商品编号 | 规格 | 价格 | 会员价 | 是否有货 | 数量 |
|---|---|---|---|---|---|
| PL03333-5mg | 5mg | ¥1366.00 | 请登录 |
|
|
| PL03333-10mg | 10mg | ¥2410.00 | 请登录 |
|
|
| PL03333-25mg | 25mg | ¥6027.00 | 请登录 |
|
|
| PL03333-50mg | 50mg | ¥10045.00 | 请登录 |
|
|
| PL03333-100mg | 100mg | ¥18001.00 | 请登录 |
|
|
| PL03333-200mg | 200mg | 询价 | 询价 |
|
|
| PL03333-500mg | 500mg | 询价 | 询价 |
|
|
| PL03333-10mM*1mLinDMSO | 10mM*1mLinDMSO | ¥2526.00 | 请登录 |
|
| 中文名称 |
CKI-7 free base
|
|---|---|
| 中文别名 |
蛋白激酶抑制剂CKI-7(PKI)
|
| 英文名称 |
CKI-7 free base
|
| 英文别名 |
N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulphonamide;N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulfonamide;CKI-7;8-Isoquinolinesulfonamide,N-(2-aminoethyl)-5-chloro-;2csn;8-Isoquinolinesulfonamide,N-(2-aminoethyl)-5-chloro;CKI;N-(2-Aminoethyl)-5-chloro-8-isoquinolinesulfonamide;N-(2-AMinoethyl)-5-chloro-isoquinolin-8-sulphonaMide;8-[N-(2-Aminoethyl)sulphamoyl]-5-chloroisoquinoline, CKI-7;8-Isoquinolinesulfonamide, N-(2-aminoethyl)-5-chloro- Dihydrochloride;CKI-7 free base
|
| Cas No. |
120615-25-0
|
| 分子式 |
C11H12N3O2Scl
|
| 分子量 |
285.75
|
| 包装储存 |
Powder -20°C 3 years；4°C 2 years
|
| 产品详情 |
CKI-7 free base 是一种有效且 ATP 竞争性的酪蛋白激酶 1 (CK1) 抑制剂，IC50 为 6 μM，Ki 为 8.5 μM。CKI-7 free base 选择性抑制 Cdc7 激酶，还抑制 SGK，S6K1 以及 MSK1。CKI-7 free base 对酪蛋白激酶 II 和其他蛋白激酶的作用弱得多。
|
|---|---|
| 生物活性 |
CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC 50 of 6 μM and a K i of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases.
|
| 性状 |
Solid
|
| IC50 & Target[1][2] |
CK1 6 μM (IC50) CK1 8.5 μM (Ki)
|
| 体外研究(In Vitro) |
CKI-7 (0.1-10 μM; 5 days; ES cells) treatment significantly increases the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers nestin and βIII-tubulin, in a concentration-dependent manner.CKI-7 (5 μM; 5 days; ES cells) treatment suppresses SFEB-induced β-catenin stabilization on day 5, indicating that CKI-7 inhibits Wnt signaling. has not independently confirmed the accuracy of these methods. They are for reference only. <
|
| 体内研究(In Vivo) |
In vivo dose-dependent anti-tumor activity of CKI-7 is demonstrated in a SCID-Beige mouse systemic tumor model utilzing a recently isolated Philadelphia chromosome positive acute lymphoblastic leukemia cell line. Standard cell cycle synchronization studies established that exposure to CKI-7 results in cell cycle dependent caspase 3 activation and apoptotic cell death. has not independently confirmed the accuracy of these methods. They are for reference only.
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Powder -20°C 3 years；4°C 2 years
|
| 参考文献 |
[1]. Osakada F, et al. In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction. J Cell Sci. 2009 Sep 1;122(Pt 17):3169-79.[2]. Mark G. Frattini, et al. Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo. Blood (2008) 112 (11): 2668.
|
| 溶解度数据 |
In Vitro: DMSO : 25 mg/mL (87.49 mM; Need ultrasonic)配制储备液
|
|---|
1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。
2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。
Copyright © 2025 陌孚医药 All rights reserved 未经授权禁止拷贝本站所有资料，如有违反，将追究法律责任。
沪ICP备2023012080号 | 
沪公网安备31011402010657号
扫码关注公众号
产品使用指南
